Dirhodium(II)-catalyzed [3 + 2] cycloaddition of N-arylaminocyclopropane with alkyne derivatives

• Wentong Liu,
• Yi Kuang,
• Zhifan Wang,
• Jin Zhu and
• Yuanhua Wang

Beilstein J. Org. Chem. 2019, 15, 542–550, doi:10.3762/bjoc.15.48

• ciprofloxacin and moxifloxacin (Scheme 1), and reverse transcriptase inhibitors [2], such as nevirapine. Meanwhile, since 1 contains a three-membered ring with high tension [3][4][5][6] and a nitrogen prone to single-electron oxidation, ring opening readily occurs followed by N-centered radical formation. The

5-Aminopyrazole as precursor in design and synthesis of fused pyrazoloazines

• Ranjana Aggarwal and
• Suresh Kumar

Beilstein J. Org. Chem. 2018, 14, 203–242, doi:10.3762/bjoc.14.15

• index) = 3999, which were better than the drugs NVP (nevirapine) (EC50 = 0.17 μM) and DLV (delavirdine) (EC50 = 0.16 μM). Kaswan et al. [103] reported the reaction of 5-aminopyrazoles 16/126 with chalcones 156 in DMF in the presence of inorganic base KOH for the synthesis of 5,7-diarylpyrazolo[1,5-a

Investigating the continuous synthesis of a nicotinonitrile precursor to nevirapine

• Ashley R. Longstreet,
• Suzanne M. Opalka,
• Brian S. Campbell,
• B. Frank Gupton and
• D. Tyler McQuade

Beilstein J. Org. Chem. 2013, 9, 2570–2578, doi:10.3762/bjoc.9.292

• . Box 842006 Richmond, Virginia 23284, United States 10.3762/bjoc.9.292 Abstract 2-Chloro-3-amino-4-picoline (CAPIC) is a strategic building block for the preparation of nevirapine, a widely-prescribed non-nucleosidic reverse transcriptase inhibitor for the treatment of HIV-infected patients. A

• continuous synthesis to the bromo derivative of a CAPIC intermediate, 2-bromo-4-methylnicotinonitrile, that terminates in a dead-end crystallization is described. The route uses inexpensive, acyclic commodity-based raw materials and has the potential to enable lower cost production of nevirapine as well as

• other value added structures that contain complex pyridines. The route terminates in a batch crystallization yielding high purity CAPIC. This outcome is expected to facilitate regulatory implementation of the overall process. Keywords: continuous; flow chemistry; HIV; Knoevenagel; nevirapine

Dipyridodiazepinone derivatives; synthesis and anti HIV-1 activity

• Nisachon Khunnawutmanotham,
• Nitirat Chimnoi,
• Arunee Thitithanyanont,
• Patchreenart Saparpakorn,
• Kiattawee Choowongkomon,
• Pornpan Pungpo,
• Supa Hannongbua and
• Supanna Techasakul

Beilstein J. Org. Chem. 2009, 5, No. 36, doi:10.3762/bjoc.5.36

• : AIDS; anti HIV-1 RT; dipyridodiazepinone; nevirapine; synthesis; Introduction Dipyridodiazepinone nevirapine (1) [1] (Figure 1) is a potent non-nucleoside inhibitor of human immunodeficiency virus type 1 reverse transcriptase (HIV-1 RT) and is approved as a therapeutic agent for the treatment of AIDS

• . In the clinic, nevirapine monotherapy results in relatively rapid drug resistance due to mutation of the RT enzyme. To develop a second-generation inhibitor with improved activity against the mutant RT enzyme, many efforts have been focused on the synthesis of dipyridodiazepinone derivatives [2][3][4

• inhibitors of this mutant enzyme. Some dipyridodiazepinone derivatives containing an N-methylated of lactam also exhibited good potency against the WT enzyme. The 8-amino derivative of nevirapine and its hydrochloride salt also provided interesting potency. The first two compounds, 2 and 3, were synthesized